SCHEMBL17393417

SCHEMBL17393417

COc1ccc2[nH]c(-c3ccc(-c4noc(-c5ccc(F)cc5)n4)cc3)nc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.60
▸ POLB P06746 2/20 0.60
▸ PTPN7 P35236 2/20 0.60
▸ BLM P54132 2/20 0.60
▸ WRN Q14191 2/20 0.60
▸ HSD17B10 Q99714 2/20 0.60
▸ USP2 O75604 1/20 0.60
▸ CASP1 P29466 1/20 0.60
▸ MAPT P10636 5/20 0.53
▸ NPC1 O15118 10/20 0.50
▸ RAB9A P51151 10/20 0.50
▸ SMN1; SMN2 Q16637 9/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ NR1H4 Q96RI1 2/20 0.50
▸ S1PR1 P21453 1/20 0.50
▸ GUSB P08236 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.47
▸ PKM P14618 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ PSMD11 O00231 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17393589 0.93 HSD17B10 (0.54) KMT2APOLBPTPN7BLMWRN
SCHEMBL17393439 0.93 NPC1 (0.58) KMT2APOLBPTPN7BLMWRN
SCHEMBL17393443 0.90 RAB9A (0.58) KMT2APOLBPTPN7BLMWRN
SCHEMBL17393742 0.90 NR1H4 (0.64) KMT2APOLBPTPN7BLMWRN
SCHEMBL17393373 0.89 SMN1; SMN2 (0.65) KMT2APOLBPTPN7BLMWRN
SCHEMBL17393702 0.89 RAB9A (0.60) KMT2APOLBHSD17B10MAPTNPC1
SCHEMBL17393743 0.88 NR1H4 (0.55) KMT2APOLBPTPN7BLMWRN
SCHEMBL17393705 0.88 RAB9A (0.56) KMT2APOLBPTPN7BLMWRN
SCHEMBL17393283 0.87 PSMD11 (0.53) KMT2APOLBPTPN7BLMWRN
SCHEMBL17393427 0.86 SMN1; SMN2 (0.57) KMT2AHSD17B10MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522907-B2 Anticancer agent and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-12-20 — — US claimed
EP-2966073-B1 DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2016-12-14 — — EP claimed
EP-2966073-A1 DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2016-01-13 — — EP claimed
US-20160002214-A1 ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-01-07 — — US claimed
US-9522907-B2 Anticancer agent and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-12-20 — — US disclosed
US-9522907-B2 Anticancer agent and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-12-20 — — US disclosed
EP-2966073-B1 DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2016-12-14 — — EP disclosed
EP-2966073-B1 DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2016-12-14 — — EP disclosed
EP-2966073-A1 DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2016-01-13 — — EP disclosed
EP-2966073-A1 DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2016-01-13 — — EP disclosed
US-20160002214-A1 ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-01-07 — — US disclosed
US-20150216994-A1 CONJUGATED PROTEINS AND PEPTIDES ABZENA (CAMBRIDGE) LIMITED (GB) 2015-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150216994-A1 CONJUGATED PROTEINS AND PEPTIDES CRKL, C1QBP, ARGLU1 KMT2A 3311/4885POLB 3342/4885PTPN7 1465/4885
US-20160002214-A1 ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF ABCC3, CASP3, ABCC4 KMT2A 2354/4885POLB 1970/4885PTPN7 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback